Program
elritercept
Also written as “Elritercept” and “TAK-226”.
Its studies are mostly in Myelodysplastic Syndromes · Primary Myelofibrosis, led by Takeda.
Furthest: phase 3, since Jul 5, 20246 company-led studies, 6 open or runningNext primary completion: Feb 28, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 66 open or running | phase 3since Jul 5, 2024 | Jun 3, 2020 | Feb 28, 2028phase 2 · NCT05037760 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 3, 2020First study: phase 2 study in Myelodysplastic SyndromesFirst studyNCT04419649 · 210 planned · United States, Australia, Czechia and more
- Aug 23, 2021Phase 2 study in Primary MyelofibrosisNCT05037760 · 135 planned · Australia, Brazil, France and more
- Jul 5, 2024Phase 3 study in Myelodysplastic SyndromesNCT06499285 · 225 planned · United States, Australia, Brazil and more
- Dec 22, 2025Phase 2 study in Myelodysplastic SyndromesNCT07319845 · 42 planned · Japan
- Feb 6, 2026Phase 3 study in Myelodysplastic SyndromesNCT07422480 · 300 planned · United States, Argentina, Australia and more
- May 29, 2026Phase 3 study in Primary MyelofibrosisNCT07623161 · 324 planned · United States, Argentina, Australia and more
- Oct 23, 2026Primary completion moved from 2028-05-01 to 2028-09-15Date moved laterphase 3 · +5 months · NCT06499285
Ahead
- Feb 28, 2028Primary completion: phase 2 study in Primary MyelofibrosisNCT05037760
- Jun 26, 2028Primary completion: phase 2 study in Myelodysplastic SyndromesNCT07319845
- Sep 15, 2028Primary completion: phase 3 study in Myelodysplastic SyndromesNCT06499285
- Apr 30, 2029Primary completion: phase 3 study in Myelodysplastic SyndromesNCT07422480
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07623161Primary Myelofibrosis · United States, Argentina, Australia and more | 3 | Recruiting | Dec 7, 2029 | 324 |
| NCT07422480Myelodysplastic Syndromes · United States, Argentina, Australia and more | 3 | Recruiting | Apr 30, 2029 | 300 |
| NCT07319845Myelodysplastic Syndromes · Japan | 2 | Recruiting | Jun 26, 2028 | 42 |
| NCT06499285Myelodysplastic Syndromes · United States, Australia, Brazil and more | 3 | Recruiting | Sep 15, 2028 | 225 |
| NCT05037760Primary Myelofibrosis · Australia, Brazil, France and more | 2 | Recruiting | Feb 28, 2028 | 135 |
| NCT04419649Myelodysplastic Syndromes · United States, Australia, Czechia and more | 2 | Recruiting | Oct 30, 2029 | 210 |
How it is read
Names in the registry
- “Elritercept”, 5 entries
- “TAK-226”, 1 entry
Conditions, from the studies’ own filings
- Myelodysplastic Syndromes, 4 studies
- Primary Myelofibrosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.